
    
      This study will be conducted in 2 parts. At the end of part 1, participants who provide
      consent and are eligible, and newly enrolled participants, will enter part 2, an Open Label
      Extension comprising a crossover analysis.

      Those participants who completed part 1 and cannot participate, or elect not to participate,
      in Part 2 (Open label extension) will enter a 12-week follow-up.
    
  